Qifan Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qifan Zhu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ankit Malik
Department of Medicine, Committee on Immunology, Department of Pediatrics, Department of Pathology, University of Chicago, Chicago, USA
1 shared publication Clifford S. Guy
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
1 shared publication- Deepika Sharma
Centre Georges François Leclerc, Dijon, France
1 shared publication - Peter Vogel
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
1 shared publication - Rajendra Karki
Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea
1 shared publication - Thirumala-Devi Kanneganti
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, USA
1 shared publication
Latest Publications
- Open Access
- 24 October 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (12) , 4469-4481
IL-33 regulates the IgA-microbiota axis to restrain IL-1α–dependent colitis and tumorigenesis
Inflammatory bowel diseases (IBD) affect over 5 million individuals in the industrialized world, with an increasing incidence rate worldwide. IBD also predisposes affected individuals to development of colorectal cancer, which is a leading cause of cancer-related deaths in adults. Mutations in genes encoding molecules in the IL-33 signaling pathway are associated with colitis and colitis-associated cancer (CAC), but how IL-33 modulates gut homeostasis is unclear. Here, we have shown that Il33-deficient mice are highly susceptible to colitis and CAC. Mechanistically, we observed that IL-33 promoted IgA production from B cells, which is important for maintaining microbial homeostasis in the intestine. Il33-deficient mice developed a dysbiotic microbiota that was characterized by increased levels of mucolytic and colitogenic bacteria. In response to chemically induced colitis, this microbial landscape promoted the release of IL-1α, which acted as a critical driver of colitis and CAC. Consequently, reconstitution of symbiotic microbiota or IL-1α ablation markedly ameliorated colitis susceptibility in Il33-deficient animals. Our results demonstrate that IL-33 promotes IgA production to maintain gut microbial homoeostasis and restrain IL-1α–dependent colitis and CAC. This study therefore highlights modulation of IL-33, IgA, IL-1α, and the microbiota as a potential therapeutic approach in the treatment of IBD and CAC.
- 24 October 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (12) , 4469-4481
Open AccessIL-33 regulates the IgA-microbiota axis to restrain IL-1α–dependent colitis and tumorigenesis
Inflammatory bowel diseases (IBD) affect over 5 million individuals in the industrialized world, with an increasing incidence rate worldwide. IBD also predisposes affected individuals to development of colorectal cancer, which is a leading cause of cancer-related deaths in adults. Mutations in genes encoding molecules in the IL-33 signaling pathway are associated with colitis and colitis-associated cancer (CAC), but how IL-33 modulates gut homeostasis is unclear. Here, we have shown that Il33-deficient mice are highly susceptible to colitis and CAC. Mechanistically, we observed that IL-33 promoted IgA production from B cells, which is important for maintaining microbial homeostasis in the intestine. Il33-deficient mice developed a dysbiotic microbiota that was characterized by increased levels of mucolytic and colitogenic bacteria. In response to chemically induced colitis, this microbial landscape promoted the release of IL-1α, which acted as a critical driver of colitis and CAC. Consequently, reconstitution of symbiotic microbiota or IL-1α ablation markedly ameliorated colitis susceptibility in Il33-deficient animals. Our results demonstrate that IL-33 promotes IgA production to maintain gut microbial homoeostasis and restrain IL-1α–dependent colitis and CAC. This study therefore highlights modulation of IL-33, IgA, IL-1α, and the microbiota as a potential therapeutic approach in the treatment of IBD and CAC.